“Potential of Clinical trials in India” by D A Prasanna presented at Bangalore India Bio, 4th June 2010

Clinical trials market in India has recorded significant growth trends in the recent past. Clinical research experienced over 84% growth during 2006-2008 and it has its own merit in regards to further prospect considering that global clinical market is growing at 12% rate. Clinical research industry in India touched US$ 320 million in 2009, up from US$ 140 million in 2006. An estimate shows that clinical research in India is expected to be US$ 320 million by 2009. According to the Associated Chambers of Commerce and Industry, an influential national industry association, India is set to grab clinical trials business valued at approximately US$ 1 billion by 2010, making the subcontinent one of the world’s most preferred destinations for clinical trials.

India presently occupies only a small quiche of the global market. The total numbers of clinical trials conducted in India were 221 in 2007 and had increased to just over 700 trials in 2008. Although there was an increase of 65%, it associates to only single digit percentage of the global clinical trial market. The country is projected to conduct nearly 50% of the global clinical trials by 2012. Clinical trials and research is now a major business in India. Over 100 companies are currently conducting the clinical trials in India. Top multinational pharmaceutical companies like Pfizer, Glaxo Smith Kline, Aventis, Novartis, Novo Nordisk, Astra Zenica, Eli Lilly are conducting clinical trials in India apart from the Indian companies like Dr. Reddys, Nicholas Piramal, Cipla and Lupin.
Read this whitepaper in PDF format
  Disclaimer | Privacy Policy | Site Map